Revenue - Viatris Agreement (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%
Upfront payment receivable	$ 205,000
Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	160,000
Revefenacin Monotherapy (TD-4208) | Success Based Development Regulatory And Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	10,000
Revefenacin Monotherapy (TD-4208) | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	150,000
Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	45,000
YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	$ 160,000
Viatris
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	65.00%
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	35.00%
Revenues	$ 16,400	$ 15,300
Viatris | Collaborative Arrangement | Collaboration revenue
Collaborative Arrangements and Co-Promote Agreement
Revenues	$ 10,411	$ 10,687